Vericel’s Proposed Public Offering of Common Stock

Vericel intends to sell shares of common stock in an underwritten public offering. Proceeds of ~US $17.0MM will support commercialization of MACI® autologous cultured chondrocytes, manufacturing and other general corporate purposes.

FDA approved MACI for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee,...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us